Ireland
--:--IST
Active, not recruiting Observational

Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility

NCT07083999 · tracked via the Priya Life Science Spain tracker
Sponsor
Procare Health Iberia S.L
Phase
Observational
Started
2025-02-13
Last updated
2026-10-06

Condition(s) studied

Fertility

Study summary

The goal of this observational study is to evaluate whether supplementation with the Ovosicare® Fertility food supplement increases the possibility of becoming pregnant in women aged between 32 and 38 years who have been trying to become pregnant for at least 6 months before starting supplementation.

Eligibility

Sex
FEMALE
Min age
32 Years
Max age
38 Years
Healthy volunteers
No
Inclusion Criteria: 1. \- Women who agree to participate in the study by signing the informed consent. 2. \- Between 32 and 38 years old. 3. \- Who come to doctor´s office stating that they have been trying to get pregnant for at least 6 months. Exclusion Criteria: 1. \- BMI \> 30 kg/m2. 2. \- Existence of severe male factor subfertility according to the criteria of the World Health Organization (WHO), with at least one analysis obtained in the last 6 months with one or more variables with values of: * Azoospermia * Progressive motility \<25% * Normal morphology ≤2% 3. \- Pregnant or breastfeeding women. 4. \- Patients with type 1 diabetes or thyroid disease. 5. \- Patients with any assisted reproduction technique scheduled during the duration of the study. 6. \- Patients who have used or taken systemic steroids, anticonvulsants, antiretroviral treatment for HIV or hepatitis B in the last month. 7. \- Patients with a known allergy to any of the components of Ovosicare® Fertility. 8. \- Any other situation that, in the medical opinion, advises against treatment with Ovosicare® Fertility or that may make patient follow-up difficult. 9. \- Patients with suspected endometriosis. 10. \- Existence of fibroids affecting the endometrial cavity. 11. \- Patients with 2 or more previous abortions. 12. \- Patients with a current diagnosis of a high-risk human papillomavirus (HPV) cervical lesion.

Primary outcome measure(s)

  • Evaluate the rate of spontaneous pregnancy in women between 32 and 38 years old after a maximum of 6 months of supplementation with Ovosicare Fertility — From enrollment to visit 2 (9 months)
    Women suspected of being pregnant will undergo a blood test to detect the hormone beta-hCG and a transvaginal ultrasound to confirm the pregnancy.

Trial sites (27)

FacilityCityRegionStatus
CM Sitges Sitges Barcelona
HU de Getafe Getafe Madrid
Clínica Rv Benalmádena Benalmádena Malaga
H García Orcoyen Estella-Lizarra Navarre
CP Dr. Andrade Andrade A Coruña Spain
CP Dra. Domenech Casanova Alicante Spain
H Vega Baja de Orihuela Alicante Spain
Clinica Alboran Almería Spain
CP Dr. Aragón Albillos Almería Spain
CM Teknon Barcelona Spain
CP Dra. Mallafre Barcelona Spain
HU Vall d'Hebron Barcelona Spain
OBS Ginecólogos Burgos Burgos Spain
Clínica Attella Castelló Spain
HU de Donostia Donostia / San Sebastian Spain
CP Dra. Skouri-Bnihech Tioua Granada Spain
CHU Insular - H Materno-Infantil Las Palmas Spain
Clínica Palacios Madrid Spain
Gymeiaka Dra. Oltra Badui Madrid Spain
Gymeiaka Dra. Pavón Sanz Madrid Spain
HU La Paz Madrid Spain
Clínica Imar Murcia Spain
Ancla Clínica Ginecológica Pontevedra Spain
HG de la Santísima Trinidad Salamanca Spain
CP Dra. Sánchez Quintana Seville Spain
HU i Politècnic la Fe Valencia Spain
Centro Ginecológico Bolonia Zaragoza Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07083999 on ClinicalTrials.gov ↗ ← All trials in Spain